Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal radiopharmaceuticals--an update.

L R Chervu, M D Blaufox

    Seminars in Nuclear Medicine
    |July 1, 1982
    PubMed
    Summary

    Radionuclide imaging offers effective, noninvasive evaluation of kidney disease, utilizing advanced radiopharmaceuticals like 99mTc-DMSA and 99mTc-DTPA. These agents provide detailed anatomical and functional insights with low radiation doses, improving diagnostic accuracy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Past, current and future developments of nuclear medicine techniques.

    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)·2002
    Same author

    (18)F-fluorodeoxyglucose positron emission tomography: false-positive lung scan.

    Seminars in nuclear medicine·2002
    Same author

    Whose liability is it anyway?

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2001
    Same author

    In vivo detection of deposition of radiolabeled lupus antikidney antibody and its inhibition by soluble antigen.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2001
    Same author

    Parenchymal mean transit time analysis of 99mTc-DTPA captopril renography.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2000
    Same author

    PET imaging in oncology.

    Seminars in nuclear medicine·2000

    Area of Science:

    • Nuclear Medicine
    • Radiopharmacology
    • Nephrology

    Background:

    • Noninvasive radionuclide imaging is increasingly recognized as a valuable alternative to traditional methods for assessing renal disease.
    • Advancements in radiopharmaceuticals, particularly those labeled with technetium-99m (99mTc), have significantly enhanced the capabilities of renal imaging.
    • Several near-ideal agents now exist for both anatomical and functional kidney assessments, delivering minimal radiation exposure.

    Purpose of the Study:

    • To highlight the growing acceptance and effectiveness of noninvasive radionuclide procedures in diagnosing renal disorders.
    • To discuss the role of advanced radiopharmaceuticals in improving the accuracy and safety of kidney evaluations.
    • To explore the potential of computer-assisted analysis of dynamic renal studies for comprehensive disease assessment.

    Main Methods:

    • Utilizing radiopharmaceuticals such as 99mTc-GHA, 99mTc-DMSA, 99mTc-DTPA, and 123I orthoiodohippurate for renal morphology and function studies.
    • Employing computer-assisted processing to analyze dynamic renal function studies, extracting parameters like extraction, uptake, and transit times.
    • Validating radionuclide procedures against established clinical techniques to confirm their diagnostic utility.

    Main Results:

    • Established radiopharmaceuticals like 99mTc-GHA, 99mTc-DMSA, and 99mTc-DTPA enable detailed renal morphology and function evaluation with low radiation doses.
    • Computer analysis of dynamic studies provides extensive data on renal handling of radiotracers, aiding in disease state identification.
    • Ongoing research seeks a 99mTc-labeled agent to replace 123I orthoiodohippurate for effective renal plasma flow (ERPF) measurements.

    Conclusions:

    • Noninvasive radionuclide imaging, supported by advanced radiopharmaceuticals and computer analysis, offers a powerful tool for evaluating renal diseases.
    • The clinical utility of these radionuclidic procedures is increasingly recognized, paving the way for routine adoption in medical facilities.
    • Further validation and development of novel agents will continue to enhance the role of radionuclide assessment in managing kidney disorders.

    Related Experiment Videos